ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Coronavirus

Thailand begins coronavirus vaccine trials on monkeys

Proposed method prompts body cells to produce antigens and molecules on virus surface

Thailand is developing one of at least 100 potential vaccines worldwide and will move from mice to monkeys in its medical trials. (Photo by Akira Kodaka) 

BANGKOK (Reuters) -- Thailand on Saturday began testing a vaccine against the coronavirus on monkeys after positive trials in mice, an official said.

Thailand's minister of higher education, science, and research and innovation, Suvit Maesincee, said researchers had moved testing of the vaccine to monkeys and hoped to have a "clearer outcome" of its effectiveness by September.

"This project is for the human race, not just Thais. The prime minister (Prayuth Chan-ocha) has outlined a policy that we must develop a vaccine and join the world community workforce on this," Suvit told reporters on Saturday.

Thailand announced on Wednesday that it was developing a vaccine - one of at least 100 potential vaccines in the works worldwide - and hoped to have it into production by next year.

Suvit said that Thailand has started reserving two manufacturers for its vaccine for COVID-19, the disease caused by the novel coronavirus.

Since the new virus emerged in China late last year, COVID-19 has spread around the world, infecting more than 5 million people and killing more than 300,000.

The Thai vaccine uses messenger RNA, which prompts body cells to produce antigens, molecules on the surface of viruses, that spur the immune system into action.

The Thai vaccine is being developed by the National Vaccine Institute, the Department of Medical Science and Chulalongkorn University's vaccine research centr

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends April 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media